High time for low-dose prospective clinical trials

Robert S. DiPaola; Henry J. Durivage; Barton A. Kamen

doi:10.1002/cncr.11709

High time for low-dose prospective clinical trials

Robert S. DiPaola, Henry J. Durivage, Barton A. Kamen

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

The article by Glode et al. in this issue reports on the empiric success, as defined by a decreased prostate specific antigen level and lack of toxicity, of metronomically delivered low-dose chemotherapy for patients with hormone-refractory prostate carcinoma. The data presented were collected as a retrospective evaluation of the medical records of patients treated with cyclophosphamide and dexamethasone who were unable to participate in Phase II drug trials or had failed previous chemotherapy regimens.

Original language	English
Pages (from-to)	1559-1561
Number of pages	3
Journal	Cancer
Volume	98
Issue number	8
DOIs	https://doi.org/10.1002/cncr.11709
State	Published - Oct 15 2003

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cncr.11709

Cite this

@article{1113bf7b5bc548028161d0c1eb18d9bc,

title = "High time for low-dose prospective clinical trials",

abstract = "The article by Glode et al. in this issue reports on the empiric success, as defined by a decreased prostate specific antigen level and lack of toxicity, of metronomically delivered low-dose chemotherapy for patients with hormone-refractory prostate carcinoma. The data presented were collected as a retrospective evaluation of the medical records of patients treated with cyclophosphamide and dexamethasone who were unable to participate in Phase II drug trials or had failed previous chemotherapy regimens.",

author = "DiPaola, {Robert S.} and Durivage, {Henry J.} and Kamen, {Barton A.}",

year = "2003",

month = oct,

day = "15",

doi = "10.1002/cncr.11709",

language = "English",

volume = "98",

pages = "1559--1561",

number = "8",

}

TY - JOUR

T1 - High time for low-dose prospective clinical trials

AU - DiPaola, Robert S.

AU - Durivage, Henry J.

AU - Kamen, Barton A.

PY - 2003/10/15

Y1 - 2003/10/15

N2 - The article by Glode et al. in this issue reports on the empiric success, as defined by a decreased prostate specific antigen level and lack of toxicity, of metronomically delivered low-dose chemotherapy for patients with hormone-refractory prostate carcinoma. The data presented were collected as a retrospective evaluation of the medical records of patients treated with cyclophosphamide and dexamethasone who were unable to participate in Phase II drug trials or had failed previous chemotherapy regimens.

AB - The article by Glode et al. in this issue reports on the empiric success, as defined by a decreased prostate specific antigen level and lack of toxicity, of metronomically delivered low-dose chemotherapy for patients with hormone-refractory prostate carcinoma. The data presented were collected as a retrospective evaluation of the medical records of patients treated with cyclophosphamide and dexamethasone who were unable to participate in Phase II drug trials or had failed previous chemotherapy regimens.

UR - http://www.scopus.com/inward/record.url?scp=0141993045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141993045&partnerID=8YFLogxK

U2 - 10.1002/cncr.11709

DO - 10.1002/cncr.11709

M3 - Review article

C2 - 14534869

AN - SCOPUS:0141993045

SN - 0008-543X

VL - 98

SP - 1559

EP - 1561

JO - Cancer

JF - Cancer

IS - 8

ER -

High time for low-dose prospective clinical trials

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this